Economic Evaluation in Genomic and Precision Medicine Translational and Applied Genomics Series
Coordonnateurs : Mitropoulou Christina, Wordsworth Sarah, Buchanan James, Patrinos George P.
2. Foundations of pharmacogenomics and personalized medicine
3. Economic evaluation of genome-guided treatment in oncology
4. Economic evaluation of rare diseases and the diagnostic odyssey
5. Economic analysis of pharmacogenetic testing for HLA-based adverse drug reactions
6. Economic evaluation of personalized medicine interventions in medium- and low-income countries with poor proliferation of genomics and genetic testing
7. Theoretical models for economic evaluation in genomic and personalized medicine
8. Using big data in economic evaluations in genomics: Challenges and opportunities
9. Assessing the stakeholder environment and views towards implementation of personalized medicine in a healthcare setting
10. Feasibility for pricing, budget allocation, and reimbursement of personalized medicine interventions
bioscientists; human geneticists; biotech industry professionals; undergraduate and graduate students in health economics and health sciences, namely medicine, pharmacy, genetics; clinicians and health managers; public health officers, health policy makers; governmental organizations; health care professionals; hospital managers
Sarah Wordsworth is at the University of Oxford, Medical Sciences Division, Nuffield Department of Population Health, Oxford, UK.
James Buchanan PhD joined the Health Economics Research Centre in 2005 and works predominantly on projects examining the economics of translating genomic high-throughput technologies from research into clinical practice, especially in cancer and infectious disease. In 2011 he was awarded a National Institute for Health Research Doctoral Research Fellowship to undertake a PhD in Health Economics investigating issues related to the economic analysis of genomic diagnostic technologies for multifactorial genetic diseases in the UK NHS, based on a study evaluating a targeted array in haematological cancers. Previous genomics projects include an economic evaluation of the use of genetic testing to identify the somatic mutations that can cause common cancers, an economic evaluation of the use of genetic tests to identify gastrointestinal pathogens to improve hospital infection control practice, the develo
- Introduces clinicians, researchers and students to essential concepts, protocols and applications of economic evaluation in genomic and precision medicine
- Demonstrates, through foundational chapters and discipline-specific case studies, how to assess the relative costs and outcomes of different genomic care pathways and implement cost-effective budgets
- Establishes clear precedents on how genomic technologies can be leveraged to simultaneously reduce costs and enhance the value of healthcare
- Features contributions from leading international medical geneticists and health economists that are actively evolved in economic assessments of genomic and precision medicine
Date de parution : 04-2023
Ouvrage de 170 p.
19x23.3 cm